KR101992331B1 - Leuconostoc citreum WiKim0059 having skin whitening and skin moisturizing activities and composition for comprising the same - Google Patents
Leuconostoc citreum WiKim0059 having skin whitening and skin moisturizing activities and composition for comprising the same Download PDFInfo
- Publication number
- KR101992331B1 KR101992331B1 KR1020170152396A KR20170152396A KR101992331B1 KR 101992331 B1 KR101992331 B1 KR 101992331B1 KR 1020170152396 A KR1020170152396 A KR 1020170152396A KR 20170152396 A KR20170152396 A KR 20170152396A KR 101992331 B1 KR101992331 B1 KR 101992331B1
- Authority
- KR
- South Korea
- Prior art keywords
- wikim0059
- present
- composition
- leuconostoc
- skin
- Prior art date
Links
- 241001468192 Leuconostoc citreum Species 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title abstract description 45
- 230000003020 moisturizing effect Effects 0.000 title abstract description 16
- 230000002087 whitening effect Effects 0.000 title abstract description 14
- 235000013305 food Nutrition 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 208000000069 hyperpigmentation Diseases 0.000 claims description 4
- 230000003810 hyperpigmentation Effects 0.000 claims description 4
- 206010014970 Ephelides Diseases 0.000 claims description 2
- 208000003351 Melanosis Diseases 0.000 claims description 2
- 235000015140 cultured milk Nutrition 0.000 claims description 2
- 241000192132 Leuconostoc Species 0.000 claims 6
- 208000003367 Hypopigmentation Diseases 0.000 claims 1
- 230000003425 hypopigmentation Effects 0.000 claims 1
- 206010024217 lentigo Diseases 0.000 claims 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 26
- 241001465754 Metazoa Species 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 12
- 206010015150 Erythema Diseases 0.000 abstract description 10
- 231100000321 erythema Toxicity 0.000 abstract description 9
- 239000006041 probiotic Substances 0.000 abstract description 9
- 235000018291 probiotics Nutrition 0.000 abstract description 9
- 238000001704 evaporation Methods 0.000 abstract description 8
- 230000008020 evaporation Effects 0.000 abstract description 8
- 230000000529 probiotic effect Effects 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 4
- 235000021109 kimchi Nutrition 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 150000007513 acids Chemical class 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 15
- 239000003674 animal food additive Substances 0.000 description 14
- 239000004310 lactic acid Substances 0.000 description 12
- 235000014655 lactic acid Nutrition 0.000 description 12
- 244000005700 microbiome Species 0.000 description 12
- 239000002537 cosmetic Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- -1 tracant Substances 0.000 description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010051246 Photodermatosis Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000008845 photoaging Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- VNPMDUDIDCXVCH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(3-piperazin-1-ylpropyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(CCCN2CCNCC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VNPMDUDIDCXVCH-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/31—Leuconostoc
- A23V2400/315—Citreum
-
- A23Y2260/21—
Abstract
본 발명은 김치로부터 분리된 신규한 류코노스톡 시트리움 WiKim0059(Leuconostoc citreum WiKim0059) 및 이를 포함하는 조성물에 관한 것이다. 본 발명에 따른 류코노스톡 시트리움 WiKim0059은 멜라닌 및 홍반 생성 억제, 경피수분증발량 감소 활성을 갖는 프로바이오틱스로서, 사람 또는 동물의 피부미백, 보습 개선, 정장 등의 용도를 위해 다양하게 활용될 수 있다. The present invention relates to compositions containing the novel acids Pocono stock sheet Solarium WiKim0059 (Leuconostoc citreum WiKim0059) separated from Kimchi, and this. Leukoostocitriium WiKim0059 according to the present invention is a probiotic having an activity of inhibiting melanin and erythema formation and reducing the amount of transdermal water evaporation, and can be variously used for skin whitening of human or animal, improvement of moisturizing, and so on.
Description
본 발명은 신규한 류코노스톡 시트리움 균주 및 이를 포함하는 조성물에 관한 것이다.The present invention relates to a novel strain of Ryukono Stokitium and a composition comprising the same.
태양 빛 중 자외선은 체내에서 비타민 D를 합성하고, 살균작용의 역할이 있으나, 피부염, 피부암, 일광 화상, 피부노화, 건조, 잔주름 등을 생기게도 한다. 자외선 중간 파장인 UVB(290-320nm)는 급성이나 만성적으로 노출되었을 경우, 심각한 피부 손상을 야기하는데, 피부 진피 내 구성성분이 콜라겐, 엘라스틴, 히알루론산을 파괴하여 피부의 탄력 손실을 유도하게 되어 그 결과 굵은 주름이 생성된다. 이러한 특징적인 변화들은 광 노화를 유도하며 피부 홍반이나 거칠기를 유도하는 것으로 알려져 있다. Ultraviolet rays in sunlight synthesizes vitamin D in the body, and it plays a role of sterilization, but it also causes dermatitis, skin cancer, sunburn, skin aging, drying, and fine wrinkles. UVB (290-320nm), which is the mid-wavelength of ultraviolet rays, causes serious skin damage when exposed to acute or chronic skin. The ingredients in skin dermis break down collagen, elastin and hyaluronic acid, The result is a thick wrinkle. These characteristic changes are known to induce photoaging and induce skin erythema and roughness.
또한, 광 노화로 인해 흑화 증상이 발생되는데, 이는 피부색을 결정하는 가장 중요한 색소인 멜라닌에 의한다. 멜라닌은 기저층에 존재하는 멜라노사이트 내의 멜라노좀에서 합성되며, 피부 세포 내의 멜라닌 양에 영향을 받게 된다. 이러한 광 노화에 의한 피부손상을 예방하기 위한 노력으로 주름, 보습 및 흑화 개선 화장료로써 유산균, 효모와 같은 미생물을 화장품 산업에 사용하는 예도 증가되고 있다. In addition, blackening occurs due to photoaging, which is caused by melanin, which is the most important pigment that determines skin color. Melanin is synthesized in the melanosomes in the melanocytes in the basal layer and is affected by the amount of melanin in the skin cells. In an effort to prevent skin damage caused by such photoaging, microorganisms such as lactic acid bacteria and yeast are used in the cosmetics industry as wrinkle, moisturizing and blackening improving cosmetic materials.
유산균은 인체 내에서 유익한 역할을 하는 미생물로서, 특히, 위 장관 면역 증강의 생리활성을 가진다고 알려져 있으며, 최근에는 경구섭취 하였을 때 피부세포의 면역조절에도 영향을 끼친다는 보고들이 있다. 하지만 유산균의 발효액, 배양액이 아닌 유산균 자체의 생균 섭취와 관련된 피부미백 및 보습 개선 효과에 대해서는 아직 알려진 바가 없다.Lactic acid bacteria are known to have a physiological activity of gastric enhancement in particular as microorganisms which play a beneficial role in the human body. Recently, there have been reports that the oral bacteria have an effect on the immune regulation of skin cells when ingested orally. However, it is not yet known whether the skin whitening and moisturizing effect of the fermentation broth of lactic acid bacteria, the culture broth of lactic acid bacteria itself, and the ingestion of live bacteria are related.
본 발명은 피부미백 및 보습개선 활성이 우수한 신규한 류코노스톡 속 유산균을 제공하고자 한다.The present invention is to provide a novel Lactobacillus sp. Lactic acid bacteria having excellent skin whitening and moisturizing activity.
이에, 본 발명자들은 전통발효식품으로부터 프로바이오틱스로서 우수한 효과를 나타내면서 피부미백 및 보습개선 효과를 나타내는 유산균 균주를 찾고자 노력한 결과, 신규한 류코노스톡 속 유산균 균주인 류코노스톡 시트리움 WiKim0059(Leuconostoc citreum WiKim0059)을 분리, 동정하여 본 발명을 완성하게 되었다.Accordingly, the present inventors have made efforts to find a lactic acid bacterial strain exhibiting skin whitening and moisturizing effect while exhibiting an excellent effect as a probiotic from a conventional fermented food. As a result, the present inventors have found that a novel strain of Leuconostoc citreum WiKim0059, And the present invention was completed.
본 발명에 따른 류코노스톡 시트리움 WiKim0059(Leuconostoc citreum WiKim0059)은 김치 유래의 류코노스톡 시트리움 신규 균주이다. 비록 본 발명에서의 류코노스톡 시트리움 WiKim0059을 김치에서 분리, 동정하기는 했으나, 이의 입수 경로가 이에 한정되는 것은 아니다. In accordance with the present invention, Leukonostocitrium WiKim0059 ( Leuconostoc citreum WiKim0059) is a new strain of Ryukonosystorium originating from kimchi. Although the present invention isolates and identifies Ryukonosystolicium WiKim0059 from kimchi, the route of its intake is not limited thereto.
본 발명에의 실시예를 통해 분리된 전통발효식품으로부터 프로바이오틱스로서 우수한 효과를 나타내는 유산균 균주는 미생물의 동정 및 분류를 위한 16S rDNA 염기서열 분석 결과, SEQ ID NO: 1의 핵산서열을 갖는 것으로 나타났다. The lactic acid bacteria strain showing excellent effect as probiotics from the conventional fermented food separated through the examples of the present invention has a nucleotide sequence of SEQ ID NO: 1 as a result of 16S rDNA sequence analysis for identification and classification of microorganisms.
따라서, SEQ ID NO: 1의 16S rDNA 염기서열을 갖는 본 발명의 미생물을 류코노스톡 시트리움 WiKim0059(Leuconostoc citreum WiKim0059)로 명명하였으며, 한국미생물보존센터에 2017년 10월 18일자로 기탁하였다(수탁번호 KCCM12131P).Therefore, the microorganism of the present invention having the 16S rDNA nucleotide sequence of SEQ ID NO: 1 was transformed into Leuconostoc citreum WiKim0059) and deposited at the Korean Microorganism Conservation Center on Oct. 18, 2017 (Accession No. KCCM12131P).
본 발명의 류코노스톡 시트리움 WiKim0059은 그람양성균이고 호기적 조건과 혐기적 조건에서 모두 성장이 가능한 통성 혐기성(facultative anaerobe)이며, 포자를 형성하지 않고 운동성이 없으며 세포는 단일 또는 쌍구균의 형태를 취하고 있다. Leukoostocitrium WiKim0059 of the present invention is a facultative anaerobe capable of growth in both aerobic and anaerobic conditions, is gram-positive, is spore-free, has no motility, and the cells take the form of single or double bacteria have.
본 발명의 류코노스톡 시트리움 WiKim0059은 프로바이오틱스로서, 유산균의 일반적인 정장 효과 및 면역 증강 효과를 갖는다. 류코노스톡 속의 유산균이 정장 효과 면역 증강 효과를 갖는다는 것은 잘 알려져 있는 사실이다.Leuconostocitrium WiKim0059 of the present invention is a probiotic, and has general dressing effect and immunity enhancing effect of lactic acid bacteria. It is well known that Lactobacillus lactobacillus has an effect of enhancing the effect of succulent action.
본 발명에 있어서, '프로바이오틱스(probiotics)'는 사람을 포함한 동물의 위장관 내에서 숙주의 장내 미생물 환경을 개선하여 숙주의 건강에 유익한 영향을 주는 살아있는 미생물'이라는 의미로 이해된다. 프로바이오틱스는 프로바이오틱 활성을 갖는 살아있는 미생물로 단일 또는 복합균주 형태로 사람이나 동물에 건조된 세포 형태나 발효산물 형태로 급여될 경우, 숙주의 장내 균총에 유익한 영향을 미칠 수 있다. In the present invention, 'probiotics' are understood to mean living microorganisms which improve the intestinal microbial environment of a host in the gastrointestinal tract of an animal including a human, thereby beneficially affecting the health of the host. Probiotics are live microorganisms with probiotic activity and can be beneficially beneficial to host intestinal microflora when fed in human or animal-dried cell form or in fermented product form in the form of single or complex strains.
하기 실시예에서는, 본 발명의 류코노스톡 시트리움 WiKim0059이 UVB 조사 무모 마우스에서 광 손상에 의해 유도되는 멜라닌 및 홍반을 억제하고, 경피수분증발량을 감소시킴으로써 류코노스톡 시트리움 WiKim0059 균주가 피부미백 및 보습개선 효과를 나타내는 것을 확인하였다. 따라서, 본 발명에 따른 류코노스톡 시트리움 WiKim0059은 프로바이오틱스로서 사람 또는 동물의 정장, 면역강화, 피부미백 및 보습개선의 용도를 위해 다양하게 활용될 수 있다. In the following Examples, leuconosystiarium WiKim0059 of the present invention suppresses melanin and erythema induced by light damage in UVB-irradiated hairless mice and reduces the amount of transdermal water evaporation, It was confirmed that the moisturizing effect was improved. Accordingly, the present invention can be applied to a variety of uses for probiotics, for the purpose of improving human or animal suitability, immunity enhancement, skin whitening and moisturizing improvement.
이에, 본 발명의 한 구체예에서는 류코노스톡 시트리움 WiKim0059 또는 이의 배양물을 포함하는 프로바이오틱스 조성물을 제공한다. Thus, in one embodiment of the present invention there is provided a probiotic composition comprising Leuconostocissium WiKim0059 or a culture thereof.
본 발명에 따른 조성물에 포함되는 류코노스톡 시트리움 WiKim0059은 생균체 또는 사균체로서 존재할 수 있으며, 또한 건조 또는 동결건조된 형태로 존재할 수도 있다. 다양한 조성물 내에 포함시키기 적합한 유산균의 형태 및 제제화 방법은 당업자에게 잘 알려져 있다. Leukoostocitriium WiKim0059 contained in the composition according to the present invention may exist as living cells or dead cells, and may also be present in a form of dried or lyophilized. The forms and formulations of lactic acid bacteria suitable for inclusion in the various compositions are well known to those skilled in the art.
한 구체예에서, 상기 조성물은 생균으로 존재하는 류코노스톡 시트리움 WiKim0059 균주를 포함하는 경구 투여용 조성물일 수 있다.In one embodiment, the composition may be a composition for oral administration comprising a strain of Ryukono Stokesium WiKim0059 present as a live bacterium.
다른 한 구체예에서, 상기 조성물은 류코노스톡 시트리움 WiKim0059 균주 또는 이의 배양물을 포함하는 피부 도포용 조성물일 수 있다.In another embodiment, the composition may be a composition for application to the skin comprising a strain of Mycobacterium tuberculosis WiKim0059 or a culture thereof.
또한, 본 발명의 한 구체예에서는 류코노스톡 시트리움 WiKim0059 또는 이의 배양물을 포함하는 정장제 조성물을 제공한다. 본 발명에 따른 정장제 조성물은 사람을 포함한 동물의 위장 질환의 예방, 치료, 개선에 이용될 수 있으며, 바람직하게는 상기 동물은 소, 말, 돼지와 같은 가축을 포함한다. 상기 '위장 질환'으로는 위장 위해 세균감염 및 염증성 장 질환을 모두 포함하며, 예를 들어 병원성 미생물(대장균, 살모넬라, 클로스트리디움 등)에 의한 감염성 설사, 위장염증, 염증성 장 질환, 신경성 장염 증후군, 소장 미생물 과성장증, 장 급이성 설사 등을 포함하지만, 이에 한정되는 것은 아니다. In addition, in one embodiment of the invention, there is provided a formulant composition comprising Liuconostocitrium WiKim0059 or a culture thereof. The composition according to the present invention can be used for prevention, treatment, and improvement of gastrointestinal diseases in animals including humans, and preferably the animals include cattle such as cows, horses, and pigs. Examples of the gastrointestinal diseases include infectious diarrhea caused by pathogenic microorganisms (Escherichia coli, Salmonella, Clostridium, etc.), gastrointestinal inflammation, inflammatory bowel disease, neurogenic enteritis syndrome , Intestinal microorganisms and growths, intestinal diarrhea, and the like.
본 발명에 따른 정장제 조성물은 경구로 투여하는 것이 바람직하다. 투여량은 위장 질환의 종류, 질환의 정도, 연령, 성별, 인종, 치료 또는 예방 목적 등에 따라 달라질 수 있으나, 일반적으로 성인을 기준으로 하루에 1천만 마리에서 1,000억마리를 투여할 수 있다. The composition of the present invention is preferably orally administered. The dose may vary depending on the type of gastrointestinal disorder, the degree of disease, age, sex, race, treatment or prevention purpose, but generally 10 to 100 billion can be administered on an adult basis.
본 발명은 류코노스톡 시트리움 WiKim0059 또는 이의 배양물을 포함하는 면역 증강용 조성물을 제공한다. 류코노스톡 속의 유산균이 정장 효과 면역 증강 효과를 갖는다는 것은 잘 알려져 있는 사실이다. The present invention provides immunoconjugate compositions comprising Leuconostocitrium WiKim0059 or a culture thereof. It is well known that Lactobacillus lactobacillus has an effect of enhancing the effect of succulent action.
본 발명은 류코노스톡 시트리움 WiKim0059 또는 이의 배양물을 포함하는 피부미백 및 보습개선용 조성물을 제공한다. 또한, 본 발명은 과색소 침착(hypopigmentation)의 예방, 개선 및 치료용 조성물을 제공한다. 상기 과색소 침착은 자외선 조사에 의한 멜라닌 과잉 합성 및 축적에 따른 색소 침착으로, 예컨대 기미, 주근깨 또는 흑자를 포함할 수 있다.The present invention provides a composition for improving skin whitening and moisturizing, which comprises Ryukonosost Citrifolia WiKim0059 or a culture thereof. The present invention also provides a composition for preventing, improving and treating hyperpigmentation. The hyperpigmentation may include hyperpigmentation due to excessive melanin synthesis and accumulation by ultraviolet irradiation, for example, spots, freckles or surplus.
본 발명에 있어서, “피부 미백”은 자외선 조사에 따른 색소 침착이나 홍반 및 멜라닌의 생성을 억제, 감소 또는 개선시키는 효과를 의미한다.In the present invention, " skin whitening " means an effect of inhibiting, reducing or improving pigment deposition, erythema and melanin production upon irradiation with ultraviolet rays.
본 발명에 있어서, “보습 개선”은 경피의 수분 증발량이 감소되는 효과를 의미한다.In the present invention, the term " moisturizing " means an effect of reducing the amount of transdermal moisture evaporation.
본 발명에 따른 류코노스톡 시트리움 WiKim0059은 이러한 유리한 작용으로 인해 의약, 건강기능식품, 식품, 사료, 사료 첨가제, 유산균 스타터 또는 화장료 내에 포함될 수 있다. According to the present invention, the leukoconstriction virus WiKim0059 according to the present invention can be contained in medicines, health functional foods, foods, feeds, feed additives, lactic acid bacteria starters or cosmetics.
한 구체예에서, 본 발명의 조성물이 약제학적 조성물로 활용될 경우, 본 발명의 약제학적 조성물은 상기 유효성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.In one embodiment, when the composition of the present invention is used as a pharmaceutical composition, the pharmaceutical composition of the present invention may be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants other than the above-mentioned effective ingredients, A disintegrant, a sweetening agent, a binder, a coating agent, a swelling agent, a lubricant, a lubricant or a flavoring agent may be used.
상기 약제학적 조성물은 투여를 위해서 상기 기재한 유효성분 이외에 추가로 약제학적으로 허용가능한 담체를 1종 이상 포함하여 약제학적 조성물로 바람직하게 제제화할 수 있다.The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.
예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연당, 옥수수감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐아세테이트, 소듐 클로라이드등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸셀룰로스, 아가, 벤토니트, 잔탄검 등을 포함한다. 액상 용액으로 제제화되는 조성물에 있어서 허용가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충식염수, 알부민 주사 용액, 덱스트로즈 용액, 말토덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다.For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, Sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
나아가 해당 분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다.Further, it can be suitably formulated according to each disease or ingredient by using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
다른 구체예에서, 본 발명은 류코노스톡 시트리움 WiKim0059 또는 이의 배양물을 유효성분으로 포함하는 피부미백 및 보습 개선용 식품일 수 있다. 상기 식품 조성물은 건강기능식품 또는 음료, 바 등의 형태를 포함할 수 있다. In another embodiment, the present invention may be a skin whitening and moisturizing improving food comprising as an active ingredient leukocystocitumium WiKim0059 or a culture thereof. The food composition may include forms such as health functional foods or beverages, bars, and the like.
본 발명에 있어서, 상기 균주를 유효성분으로 포함하는 식품 조성물은 발효유 등의 음료를 포함할 수 있다. 이에, 본 발명은 류코노스톡 시트리움 WiKim0059 또는 이의 배양물로 이루어지는 발효용 유산균 스타터를 제공한다.In the present invention, the food composition containing the strain as an active ingredient may include beverages such as fermented milk. Accordingly, the present invention provides a lactic acid bacteria starter for fermentation comprising Ryukonosystiatisum WiKim0059 or a culture thereof.
본 발명에 따른 식품 조성물은 상기 약제학적 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 비타민 복합제, 건강보조 식품류 등이 있다.The food composition according to the present invention can be formulated in the same manner as the above pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, vitamin complexes, and health supplement foods.
본 발명의 식품 조성물은 식품 제조시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아추출물 (예를 들어 레바우디오시드A, 글리시르히진 등]) 및 합성향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제와 음료류로 제조되는 경우에는 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각 종 식물 추출액 등을 추가로 포함시킬 수 있다.The food composition of the present invention may contain components that are conventionally added during the manufacture of a food product, including, for example, proteins, carbohydrates, fats, nutrients, flavoring agents, and flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, when the food composition of the present invention is prepared from a drink and beverage, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be further added.
상기 본 발명에 따른 조성물은 사료첨가제 또는 사료로서 이용될 수 있다.The composition according to the present invention can be used as a feed additive or feed.
사료 첨가제로서 이용될 경우, 상기 조성물은 20 내지 90% 고농축액이거나 분말 또는 과립 형태로 제조될 수 있다. 상기 사료첨가제는 구연산, 후말산, 아디픽산, 젖산, 사과산 등의 유기산이나 인산 나트륨, 인산 칼륨, 산성 피로인산염, 폴리인산염(중합인산염) 등의 인산염이나, 폴리페놀, 카테킨, 알파-토코페롤, 로즈마리 추출물, 비타민 C, 녹차 추출물, 감초 추출물, 키토산, 탄닌산, 피틴산 등의 천연 항산화제 중 어느 하나 또는 하나 이상을 추가로 포함할 수 있다. 사료로서 이용될 경우, 상기 조성물은 통상의 사료 형태로 제제화될 수 있으며, 통상의 사료성분을 함께 포함할 수 있다.When used as a feed additive, the composition may be 20 to 90% high concentrate or may be prepared in powder or granular form. The feed additive may be selected from the group consisting of organic acids such as citric acid, fumaric acid, adipic acid, lactic acid and malic acid, phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polymerized phosphate), polyphenol, catechin, alpha-tocopherol, Extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, phytic acid, and the like. When used as a feed, the composition may be formulated in conventional feed form and may contain conventional feed ingredients.
상기 사료첨가제 및 사료는 곡물, 예를 들면 분쇄 또는 파쇄된 밀, 귀리, 보리, 옥수수 및 쌀; 식물성 단백질 사료, 예를 들면 평지, 콩, 및 해바라기를 주성분으로 하는 사료; 동물성 단백질 사료, 예를 들면 혈분, 육분, 골분 및 생선분; 당분 및 유제품, 예를 들면 각종 분유 및 유장 분말로 이루어지는 건조성분 등을 더 포함할 수 있으며, 이외에도 영양보충제, 소화 및 흡수향상제, 성장촉진제 등을 더 포함할 수 있다.The feed additives and feeds may be selected from the group consisting of cereals, such as ground or crushed wheat, oats, barley, corn and rice; Feeds based on vegetable protein such as rapeseed, soybeans and sunflower; Animal protein feeds such as blood, meat, bone meal and fish meal; A sugar or a milk product, for example, a dry component comprising various powdered milk and whey powder, and may further include nutritional supplements, digestion and absorption enhancers, growth promoters, and the like.
상기 사료첨가제는 동물에게 단독으로 투여하거나 식용 담체 중에서 다른 사료첨가제와 조합하여 투여할 수도 있다. 또한, 상기 사료첨가제는 탑드레싱으로서 또는 이들을 동물사료에 직접 혼합하거나 또는 사료와 별도의 경구제형으로 용이하게 동물에게 투여할 수 있다. 상기 사료첨가제를 동물사료와 별도로 투여할 경우, 당해 기술분야에 잘 알려진 바와 같이 약제학적으로 허용가능한 식용 담체와 조합하여, 즉시 방출 또는 서방성 제형으로 제조할 수 있다. 이러한 식용 담체는 고체 또는 액체, 예를 들어 옥수수전분, 락토오스, 수크로오스, 콩플레이크, 땅콩유, 올리브유, 참깨유 및 프로필렌글리콜일 수 있다. 고체 담체가 사용될 경우, 사료첨가제는 정제, 캡슐제, 산제, 트로키제 또는 함당정제 또는 미분산성 형태의 탑 드레싱일 수 있다. 액체 담체가 사용될 경우, 사료첨가제는 젤라틴 연질 캡슐제, 또는 시럽제나 현탁액, 에멀젼제, 또는 용액제의 제형일 수 있다. The feed additive may be administered to animals singly or in combination with other feed additives in edible carriers. The feed additives can also be administered to the animal either as a top dressing or they can be mixed directly with the animal feed or in a separate oral form separate from the feed. When the feed additive is administered separately from an animal feed, it can be prepared in an immediate release or sustained release formulation, in combination with a pharmaceutically acceptable edible carrier as is well known in the art. Such edible carriers may be solid or liquid, such as corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol. When a solid carrier is used, the feed additive can be a tablet, capsule, powder, troche or emulsion or top-dressing in finely divided form. When a liquid carrier is used, the feed additive can be a gelatin soft capsule, or a syrup or suspension, emulsion, or solution formulation.
또한, 상기 사료첨가제 및 사료는 보조제, 예를 들어 보존제, 안정화제, 습윤제 또는 유화제, 용액촉진제 등을 함유할 수 있다. 상기 사료첨가제는 침주, 분무 또는 혼합하여 동물의 사료에 첨가하여 이용될 수 있다.The feed additives and feeds may also contain adjuvants such as preservatives, stabilizers, wetting or emulsifying agents, solution promoters and the like. The feed additive may be used by adding to the animal's feed by pouring, spraying or mixing.
본 발명의 사료 또는 사료첨가제는 포유류, 가금 및 어류를 포함하는 다수의 동물식이에 적용할 수 있다.The feed or feed additive of the present invention can be applied to a number of animal diets including mammals, poultry, and fish.
상기 포유류로서 돼지, 소, 양, 염소, 실험용 설치동물, 및 실험용 설치동물뿐만 아니라, 애완동물(예: 개, 고양이) 등에게 사용할 수 있으며, 상기 가금류로서 닭, 칠면조, 오리, 거위, 꿩, 및 메추라기 등에도 사용할 수 있고, 상기 어류로서 송어 등에 이용될 수 있으나, 이에 한정되는 것은 아니다.The above-mentioned mammals can be used for pets (for example, dogs and cats) as well as pigs, cows, sheep, goats, laboratory animals and laboratory animals as well as poultry such as chicken, turkey, duck, goose, And quail, and the fish can be used as trout, but the present invention is not limited thereto.
본 발명에 따른 조성물에 포함되는 류코노스톡 시트리움 WiKim0059 균주의 양은 1회를 기준으로 약 106 내지 1012 cfu/g일 수 있으며, 예컨대 107 내지 1011 cfu/g, 108 내지 1010 cfu/g일 수 있다. 균주를 투여할 경우에는 생균 상태로 투여하는 것이 바람직하며, 섭취 전에 사멸시키거나 감쇄(attenuation) 상태로 투여할 수 있다. 또한, 배양 상등액 등을 사용하여 제조할 경우에는 열처리 과정을 통한 멸균화 과정을 추가적으로 거칠 수 있다. 최소의 효능을 가지는데 필요한 균주량 및 일일 섭취 정도는 섭취자의 신체 또는 건강상태에 따라 달라질 수 있으나, 일반적으로 약 106 내지 1012 cfu/g일 수 있으며, 예컨대 107 내지 1011 cfu/g, 108 내지 1010 cfu/g일 수 있다.The amount of the Leukonoostocitriium WiKim0059 strain contained in the composition according to the present invention may be about 10 6 to 10 12 cfu / g, for example, 10 7 to 10 11 cfu / g, 10 8 to 10 10 cfu / g. When the strain is administered, it is preferable to administer the strain in a live condition, and it may be administered in an attenuation state or before the ingestion. In addition, in the case of using a supernatant of culture or the like, a sterilization process may be further performed through a heat treatment process. The amount of the bacterial strain and the daily intake required to have the minimum efficacy may vary depending on the body or health condition of the consumer, but may generally be about 10 6 to 10 12 cfu / g, for example 10 7 to 10 11 cfu / g , And 10 8 to 10 10 cfu / g.
상기 본 발명에 따른 조성물은 피부 미백 및 보습 개선용 화장료로서 이용될 수 있다.The composition according to the present invention can be used as a cosmetic for skin whitening and moisturizing.
상기 피부미백 및 보습개선은 위에서 기술한 모든 내용을 그대로 적용시킬 수 있다.The skin whitening and moisturizing improvement can be applied to all of the above-mentioned contents.
본 발명의 화장료 조성물은 화장료 제조시 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 담체 등을 포함할 수 있다. 상기 화장료 조성물은 당업계에서 통상적으로 제조되는 제형으로 제조될 수 있으며, 예컨대, 용액, 현탁액, 유탁액, 페이스트, 젤, 크림, 로션, 파우더, 비누, 오일, 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition of the present invention may contain components that are conventionally added in cosmetic preparation, and may include, for example, conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, have. The cosmetic composition may be formulated into a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, an oil, a foundation and a spray, etc. But is not limited thereto.
본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 젤인 경우, 담체 성분으로 동물성 오일, 식물성 오일, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다. 본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다. 본 발명의 화장료 조성물 제형이 용액 또는 유탁액인 경우 담체 성분으로 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다. 본 발명의 화장료 조성물의 제형이 현탁액인 경우 담체 성분으로 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a paste, a cream or a gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide Can be used. When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of spray, a mixture of chlorofluorohydrocarbons , Propane / butane or dimethyl ether. When the cosmetic composition of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethylcarbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan. When the formulation of the cosmetic composition of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments described in detail below. The present invention may, however, be embodied in many different forms and should not be construed as being limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Is provided to fully convey the scope of the invention to those skilled in the art, and the invention is only defined by the scope of the claims.
본 발명에 따른 류코노스톡 시트리움 WiKim0059은 멜라닌 생성 억제, 경피수분증발량 감소 활성을 나타내므로, 프로바이오틱스로서 사람 또는 동물의 정장, 면역강화, 위장 질환, 피부미백 및 보습 개선의 용도를 위해 다양하게 활용될 수 있다. 나아가, 발효용 스타터로서 유용하게 사용할 수 있다.As the probiotics, it is possible to use variously for the purpose of enhancing the suitability of a person or an animal, strengthening immunity, gastrointestinal disease, skin whitening, and moisturizing because the leukoconstrictor WiKim0059 according to the present invention exhibits an activity of inhibiting melanin formation and reducing the amount of transdermal moisture evaporation. . Further, it can be usefully used as a starter for fermentation.
도 1은 본 발명에 따른 WiKim0059 균주 처리에 따른 멜라닌 및 홍반 생성 억제 효과를 육안으로 관찰한 사진이다.
도 2는 본 발명에 따른 WiKim0059 균주 처리에 따른 멜라닌 정도를 측정한 그래프이다.
도 3은 본 발명에 따른 WiKim0059 균주 처리에 따른 홍반 정도를 측정한 그래프이다.
도 4는 본 발명에 따른 WiKim0059 균주 처리에 따른 경피수분증발량을 측정한 그래프이다.FIG. 1 is a photograph showing the effect of the inhibition of melanin and erythema formation according to the present invention by visual observation of a strain of WiKim0059.
FIG. 2 is a graph showing melanin level measured according to the WiKim0059 strain according to the present invention.
FIG. 3 is a graph showing erythema levels measured according to the WiKim0059 strain according to the present invention.
FIG. 4 is a graph showing the measurement of transdermal water evaporation amount according to the treatment of WiKim0059 strain according to the present invention. FIG.
이하, 본 발명을 실시예를 통해 상세히 설명한다. 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to examples. The following examples illustrate the invention and are not intended to limit the scope of the invention.
[실시예][Example]
실시예 1: 균주의 분리 및 동정Example 1: Isolation and Identification of Strain
김치 추출물의 원액을 MRS 배지에 도말하여 얻은 균단일집락을 루프로 수거하여 MRS broth에 배양하였다. DNA 추출은 QIAamp DNA Mini Kit(QIAgen, Germany)를 사용하여 추출하였다. 추출된 DNA는 1.5% 아가로스 겔을 이용하여 확인하였으며, 16S rDNA gene을 증폭하기 위하여 추출된 genomic DNA를 주형으로 하여 PCR을 진행하였고, PCR 조건은 denaturation 95℃ 1분, annealing 45℃ 1분, extension 72℃ 1분 30초로 30 사이클을 수행하였다. 얻어진 PCR 산물은 마크로젠(Seoul, Korea)에 의뢰하여 서열을 분석하였다. 세균의 동정은 16SrDNA 서열을 National Center for Biotechnology Information(NCBI, www.ncbi.nlm.nih.gov)의 Basic Local Alignment Search Tool (BLAST) 검색엔진의 유사도 분석을 통해 수행하였다. Kimchi extracts were plated on MRS broth and the resulting single colonies were collected in a loop and cultured in MRS broth. DNA extraction was performed using QIAamp DNA Mini Kit (QIAgen, Germany). PCR was carried out using genomic DNA extracted to amplify the 16S rDNA gene. The PCR conditions were denaturation at 95 ° C for 1 min, annealing at 45 ° C for 1 min, extension at 72 ° C for 1 minute and 30 seconds. The obtained PCR products were analyzed by sequencing with the request of Macrogen (Seoul, Korea). The identity of the bacteria was determined by the similarity analysis of the 16S rDNA sequence in the BLAST search engine of the National Center for Biotechnology Information (NCBI, www.ncbi.nlm.nih.gov).
본 발명의 실시예를 통해 분리된 균주는 미생물의 동정을 위한 16S rDNA 염기서열 분석 결과, SEQ ID NO: 1의 핵산서열을 갖는 것으로 나타났다. As a result of the 16S rDNA sequence analysis for isolating the microorganism, the strain isolated through the examples of the present invention has a nucleotide sequence of SEQ ID NO: 1.
이에, 본 발명의 미생물을 류코노스톡 시트리움 WiKim0059(Leuconostoc citreum WiKim0059)으로 명명하였으며, 한국미생물보존센터에 2017년 10월 18일자로 기탁하였다(KCCM12131P).Thus, the microorganism of the present invention was named Leukonostoc citreum WiKim0059 ( Leuconostoc citreum WiKim0059) and deposited at the Korean Microorganism Conservation Center on October 18, 2017 (KCCM12131P).
실시예Example 2: 류코노스톡 2: Ryukono Stock 시트리움Citium WiKim0059의WiKim0059's 피부미백Skin whitening 및 보습개선 효능 확인 And moisturizing and improving efficacy
상기 실시예 1에서 분리한 류코노스톡 시트리움 WiKim0059 균주는 MRS 배지에서 30℃, 24시간 동안 배양하고, 배양된 균체를 8,000rpm에서 5분 동안 원심분리하여 PBS로 헹군 후 남아있는 배지성분을 제거하였다. 이후, PBS를 이용하여 1ⅹ109 CFU/ml 균수로 정량하였으며, 0.1㎖(1ⅹ109 CFU)씩 존대를 이용하여 8주령의 암컷 무모 쥐 모델(female SKH hairless mice)에 UVB 조사 일주일 전부터 매일 경구 투여하였다. 이때 음성 및 양성 대조군에는 멸균된 PBS를 투여하였으며, UVB 처리는 주 3회 무모 쥐의 등 부분에 조사하고, 자외선 조사량은 1주차에 2MED (50mJ/cm2)로 조사를 시작하여 매주 1MED씩 높여서 조사하였다. 실험은 총 12주간 진행하였다.The strains of Ryukono Stokesium WiKim0059 isolated in Example 1 were cultured in MRS medium at 30 ° C for 24 hours, and the cultured cells were centrifuged at 8,000 rpm for 5 minutes, rinsed with PBS, and the remaining medium was removed Respectively. Subsequently, the cells were quantitated to 1 × 10 9 CFU / ml using PBS and 0.1 ml (1 × 10 9 CFU) was orally administered to female SKH hairless mice at 8 weeks of age each day for one week before UVB irradiation . At this time, sterilized PBS was administered to the negative and positive control. UVB treatment was applied to the dorsal part of the hairless mouse three times a week, and irradiation with UV light was started at 2MED (50 mJ / cm 2 ) Respectively. The experiment was conducted for a total of 12 weeks.
1) UVB 조사 무모 쥐 모델에서의 육안 관찰1) Visual observation of UVB-irradiated mouse model
UVB 조사 무모 쥐 모델의 류코노스톡 시트리움 WiKim0059 처리에 따른 피부를 육안으로 관찰하였다(도 1).The skin was observed with naked eyes according to the treatment of Ryukono Stokesium WiKim0059 of the UVB irradiated mouse model (Fig. 1).
그 결과, 류코노스톡 시트리움 WiKim0059 처리군(WiKim0059)에서 멜라닌 및 홍반 정도가 유의한 수준으로 감소한 것을 확인하였다.As a result, it was confirmed that the degree of melanin and erythema decreased to a significant level in the treatment group of Ryukono Stokosium WiKim0059 (WiKim0059).
2) 멜라닌 정도 측정2) Melanin level measurement
류코노스톡 시트리움 WiKim0059 균주를 실험 동물에 경구투여하여 12주 후, Mexameter(MX18)를 이용하여 멜라닌 정도를 측정하였으며, 실험동물의 등 부위 8곳을 측정하여 그 평균 값을 결과 값으로 산출하였다. Melanocytes were measured by Mexameter (MX18) after 12 weeks of oral administration to the experimental animals, and the average value of the melanin was measured at 8 sites in the back of the experimental animals .
그 결과, 도 2에서 보는 것과 같이 대조군(C)에 비해 WiKim0059 처리구에서 멜라닌 정도가 유의하게 감소한 것을 확인할 수 있으며, 정상군(N)과 비슷한 수준으로 감소된 것을 확인하였다.As a result, as shown in FIG. 2, the melanin level in the WiKim0059 treated group was significantly decreased compared to the control group (C), and it was confirmed that the melanin level was reduced to a level similar to that of the normal group (N).
3) 홍반 정도 측정3) Measuring erythema degree
류코노스톡 시트리움 WiKim0059 균주를 실험 동물에 경구투여하여 12주 후, Mexameter(MX18)를 이용하여 홍반 정도를 측정하였으며, 실험동물의 등 부위 8곳을 측정하여 그 평균 값을 결과 값으로 산출하였다. Twelve weeks after oral administration of Ryukono Stokitium WiKim0059 strain to experimental animals, the extent of erythema was measured using Mexameter (MX18), and the average value of the erythrocyte areas of the experimental animals was measured as a result .
그 결과, 도 3에서 보는 것과 같이 대조군(C)에 비해 WiKim0059 처리구에서 홍반 정도가 유의하게 감소한 것을 확인할 수 있었다.As a result, as shown in FIG. 3, it was confirmed that erythema severity was significantly reduced in the WiKim0059 treatment group as compared with the control group (C).
4) 경피수분증발량 측정4) Measurement of transdermal water evaporation
류코노스톡 시트리움 WiKim0059 균주를 실험 동물에 경구투여하여 12주 후, Tewameter를 이용하여 경피수분증발량을 측정하였으며, 실험동물 등 부위의 8곳을 측정하여 그 평균 값을 결과 값으로 산출하였다. Twelve weeks after the oral administration of the strain Liukono Stokitium WiKim0059 to experimental animals, the amount of transdermal water evaporation was measured using a tewater, and the average value of the results was measured at 8 sites in the experimental animals.
그 결과, 도 4에서 보는 것과 같이 대조군(C)에 비해 WiKim0059 처리구에서 경피수분증발량이 감소하는 것을 확인함으로써, 상기 균주 처리에 따른 피부 보습개선 효과를 확인하였다.As a result, as shown in FIG. 4, it was confirmed that the amount of percutaneous water evaporation decreased in the treatment of WiKim0059 as compared with that of the control (C).
<110> Korea Food Research Institute <120> Leuconostoc citreum WiKim0059 having skin whitening and skin moisturizing activities and composition for comprising the same <130> P17R10C1430 <160> 1 <170> KopatentIn 2.0 <210> 1 <211> 585 <212> DNA <213> Leuconostoc citreum WiKim0059 <400> 1 cgagcgcaga cggttgatta agtctgatgt gaaagcccgg agctcaactc cggaatggca 60 ttggaaactg gttaacttga gtgttgtaga ggtaagtgga actccatgtg tagcggtgga 120 atgcgtagat atatggaaga acaccagtgg cgaaggcggc ttactggaca acaactgacg 180 ttgaggctcg aaagtgtggg tagcaaacag gattagatac cctggtagtc cacaccgtaa 240 acgatgaata ctaggtgtta ggaggtttcc gcctcttagt gccgaagcta acgcattaag 300 tattccgcct ggggagtacg accgcaaggt tgaaactcaa aggaattgac ggggacccgc 360 acaagcggtg gagcatgtgg tttaattcga agcaacgcga agaaccttac caggtcttga 420 catcctttga agcttttaga gatagaagtg ttctcttcgg agacaaagtg acaggtggtg 480 catggtcgtc gtcagctcgt gtcgtgagat gttgggttaa gtcccgcaac gagcgcaacc 540 cttattgtta gttgccagca ttcagttggg cactctagcg agact 585 <110> Korea Food Research Institute <120> Leuconostoc citreum WiKim0059 having skin whitening and skin moisturizing activities and composition for the same <130> P17R10C1430 <160> 1 <170> Kopatentin 2.0 <210> 1 <211> 585 <212> DNA <213> Leuconostoc citreum WiKim0059 <400> 1 cgagcgcaga cggttgatta agtctgatgt gaaagcccgg agctcaactc cggaatggca 60 ttggaaactg gttaacttga gtgttgtaga ggtaagtgga actccatgtg tagcggtgga 120 atgggagat atatggaaga acaccagtgg cgaaggcggc ttactggaca acaactgacg 180 ttgaggctcg aaagtgtggg tagcaaacag gattagatac cctggtagtc cacaccgtaa 240 acgatgaata ctaggtgtta ggaggtttcc gcctcttagt gccgaagcta acgcattaag 300 tattccgcct ggggagtacg accgcaaggt tgaaactcaa aggaattgac ggggacccgc 360 acaagcggtg gagcatgtgg tttaattcga agcaacgcga agaaccttac caggtcttga 420 catcctttga agcttttaga gatagaagtg ttctcttcgg agacaaagtg acaggtggtg 480 catggtcgtc gtcagctcgt gtcgtgagat gttgggttaa gtcccgcaac gagcgcaacc 540 cttattgtta gttgccagca ttcagttggg cactctagcg agact 585
Claims (11)
상기 식품은 건강기능식품인 식품 조성물.3. The method of claim 2,
Wherein the food is a health functional food.
상기 식품은 음료, 바 또는 발효유인 식품 조성물.3. The method of claim 2,
Wherein the food is a beverage, bar or fermented milk.
상기 과색소 침착은 기미, 주근깨 및 흑자(lentigo)로 이루어진 군에서 선택된 하나 이상인 약학 조성물.10. The method of claim 9,
Wherein said hyperpigmentation is at least one selected from the group consisting of spots, freckles and lentigo.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170152396A KR101992331B1 (en) | 2017-11-15 | 2017-11-15 | Leuconostoc citreum WiKim0059 having skin whitening and skin moisturizing activities and composition for comprising the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170152396A KR101992331B1 (en) | 2017-11-15 | 2017-11-15 | Leuconostoc citreum WiKim0059 having skin whitening and skin moisturizing activities and composition for comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190055553A KR20190055553A (en) | 2019-05-23 |
| KR101992331B1 true KR101992331B1 (en) | 2019-06-24 |
Family
ID=66681149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170152396A KR101992331B1 (en) | 2017-11-15 | 2017-11-15 | Leuconostoc citreum WiKim0059 having skin whitening and skin moisturizing activities and composition for comprising the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101992331B1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102199062B1 (en) * | 2019-09-27 | 2021-01-06 | 코스맥스 주식회사 | Staphylococcus xylosus ST-10 strain and skin condition improving uses of thereof |
| KR102199065B1 (en) * | 2019-09-27 | 2021-01-06 | 코스맥스 주식회사 | Staphylococcus cohnii ST-3 strain and skin condition improving uses of thereof |
| KR102334457B1 (en) * | 2020-06-08 | 2021-12-03 | 코스맥스 주식회사 | Microbacterium oleivorans strain and skin condition improving uses of thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080092090A (en) * | 2007-04-11 | 2008-10-15 | 주식회사 두산 | Whitening composition containing lactobacillus lysate |
| KR101957193B1 (en) | 2012-04-13 | 2019-04-08 | 주식회사 알엔에이 | Compisitiom for anti-inflammation, skin whitening and anti-aging comprising of supernatant of lactic acid bacteria lysate |
| CA2999821C (en) * | 2014-09-30 | 2021-03-23 | Rna Inc. | Method for preparing microbial preparation and microbial preparation produced by the same |
| KR101772870B1 (en) * | 2016-02-05 | 2017-08-30 | 명지대학교 산학협력단 | Novel Lactobacillus plantarum with probiotic activities and use thereof |
-
2017
- 2017-11-15 KR KR1020170152396A patent/KR101992331B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190055553A (en) | 2019-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102070143B1 (en) | Lactobacillus plantarum WiKim0060 having skin whitening and skin moisturizing activities and composition for comprising the same | |
| JP5718916B2 (en) | Novel Lactobacillus plantarum and composition containing the same | |
| JP5791009B2 (en) | Lactic acid bacteria and food or drink using them | |
| KR101801764B1 (en) | Lactobacillus curvatus WIKIM55 having promoting the hair growth | |
| KR101992537B1 (en) | Novel Lactobacillus sakei and compositions comprising the same | |
| KR101838281B1 (en) | Lactobacillus curvatus WIKIM53 having anti-allergic disease activity and composition for comprising the same | |
| CN113498433A (en) | Composition for preventing, improving or treating obesity or fatty liver disease comprising leuconostoc citreum WIKIM0104 | |
| EP3950928A1 (en) | Kimchi lactic acid bacteria lactobacillus sakei wikim0109 having efficacy for relief of arthritis | |
| KR20190051771A (en) | Lactobacillus plantarum WiKim0062 having anti-obesity activity and composition comprising the same | |
| KR101992331B1 (en) | Leuconostoc citreum WiKim0059 having skin whitening and skin moisturizing activities and composition for comprising the same | |
| CN110651888A (en) | Method for producing fermented product of pig blood, and antibacterial composition and chicken feed composition using the fermented product | |
| CN113508173A (en) | Composition for preventing, ameliorating or treating obesity or fatty liver disease comprising WiKim0103 of Welstonia hernensis | |
| KR101834383B1 (en) | Weissella cibaria WIKIM28 having anti-obesity activity and composition for comprising the same | |
| KR101757785B1 (en) | Leuconostoc lactis WIKIM48 having high productivity of 2-hydroxyisocaproic acid and composition for comprising the same | |
| KR102313770B1 (en) | LACTOBACILLUS PLANTARUM WiKim0127 STRAIN DERIVED FROM JEJU PICKLED CABBAGE FOOD AND METHOD FOR PREPARING COMPOSITION USING SAME | |
| KR101409764B1 (en) | Comprising lactic acid fermentation product of Gelidium amansil extract as an Active Ingredient for Improving Skin Wrinkle | |
| KR101409760B1 (en) | Comprising lactic acid fermentation product of Cirsium japonicum and Gelidium amansil extract as an Active Ingredient for Improving Skin Wrinkle | |
| KR101838280B1 (en) | Leuconostoc citreum WIKIM56 having anti-arthritis activity and composition for comprising the same | |
| KR102313769B1 (en) | Lactobacillus plantarum wikim0126 strain derived from jeju pickled brussels sprout food and method for preparing composition using same | |
| KR101834379B1 (en) | Weissella confusa WIKIM51 having anti-obesity activity and composition for comprising the same | |
| KR20210086438A (en) | Bacillus subtilis strain jnucc having anti-alpha glucosidase and anti-tyrosinase activity effect and use thereof | |
| KR20190051772A (en) | Lactobacillus plantarum WiKim0061 having anti-obesity activity and composition comprising the same | |
| KR102014464B1 (en) | Tetragenococcus halophilus WiKim0082, which has betaine-producing ability, and a composition containing the same | |
| KR102457366B1 (en) | Lactobacillus plantarum wikim0127 strain derived from jeju pickled cabbage food and method for preparing composition using same | |
| KR102457367B1 (en) | Lactobacillus plantarum wikim0126 strain derived from jeju pickled brussels sprout food and method for preparing composition using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |